New Acute Myeloid Leukemia Study Findings Recently Were Reported by Researchers at University of Texas MD Anderson Cancer Center (Efficacy and Safety of Gilteritinib Versus Sorafenib As Post-transplant Maintenance In Patients With Flt3-itd...).

Předmět:	ACUTE myeloid leukemia MYELOID leukemia HEMATOPOIETIC stem cell transplantation STEM cell transplantation PROTEIN-tyrosine kinase inhibitors
Zdroj:	Clinical Trials Week; 11/25/2024, p1108-1108, 1p
Abstrakt:	Researchers at the University of Texas MD Anderson Cancer Center conducted a study comparing the efficacy and safety of two maintenance therapies, gilteritinib and sorafenib, in patients with FLT3-ITD acute myeloid leukemia post-transplant. The study found that both therapies showed similar 1-year progression-free survival rates and toxicity profiles. The research aimed to address the high relapse rate in patients with FLT3-ITD AML post-transplant and concluded that both gilteritinib and sorafenib are viable options for post-transplant maintenance therapy. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu